文献速递冠心病

SMART2算法:已确诊心血管病患者动脉粥样硬化性心血管事件复发风险预测更新

Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm.
PubMed 文献 · Eur Heart J · 2022-01-01

在Utrecht心血管队列-SMART队列8355例已确诊ASCVD患者中,采用Fine和Gray竞争风险模型推导10年ASCVD复发风险预测模型,并按欧洲四个地区及亚洲(除日本)、日本、澳大利亚、北美、拉丁美洲进行区域再校准。

要点

  • SMART2用于已确诊ASCVD患者10年复发事件的个体化风险预测。
  • 模型按多区域队列数据进行再校准,并在七个外部队列中完成验证。
  • 外部验证C统计量范围为0.605至0.772,不同队列间存在差异。

核心结论

  • SMART2风险评分是经过更新和验证的工具,可用于欧洲及非欧洲人群中已确诊ASCVD患者的ASCVD复发事件预测。
  • 该工具可能支持基于定量残余风险评估的个体化二级预防策略。

研究设计与样本

  • 从Utrecht心血管队列-SMART队列纳入冠心病、脑血管病、外周动脉疾病或腹主动脉瘤患者,n=8355,中位随访8.2年(四分位距4.2-12.5)期间发生1706例ASCVD事件。
  • 采用Fine和Gray竞争风险调整模型推导10年ASCVD复发事件(非致死性心肌梗死、非致死性卒中或心血管死亡)预测模型。
  • 模型依据欧洲四个地区以及亚洲(除日本)、日本、澳大利亚、北美和拉丁美洲的当代队列数据进行区域再校准。

主要发现

  • 外部验证C统计量范围为0.605(95%CI 0.547-0.664,BACS/BAMI)至0.772(95%CI 0.659-0.886,REACH欧洲高危地区)。
  • 模型在多个临床相关强化治疗阈值范围内显示出临床效用。

临床怎么用

  • 对已确诊ASCVD患者,可用SMART2估算10年复发ASCVD事件风险,辅助二级预防决策。
  • 风险分层可依据定量残余风险估计而非仅定性判断,以支持更个体化的管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The 10-year risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events in patients with established ASCVD can be estimated with the Secondary Manifestations of ARTerial disease (SMART) risk score, and may help refine clinical management. To broaden generalizability across regions, we updated the existing tool (SMART2 risk score) and recalibrated it with regional incidence rates and assessed its performance in external populations. METHODS AND RESULTS: Individuals with coronary artery disease, cerebrovascular disease, peripheral artery disease, or abdominal aortic aneurysms were included from the Utrecht Cardiovascular Cohort-SMART cohort [n = 8355; 1706 ASCVD events during a median follow-up of 8.2 years (interquartile range 4.2-12.5)] to derive a 10-year risk prediction model for recurrent ASCVD events (non-fatal myocardial infarction, non-fatal stroke, or cardiovascular mortality) using a Fine and Gray competing risk-adjusted model. The model was recalibrated to four regions across Europe, and to Asia (excluding Japan), Japan, Australia, North America, and Latin America using contemporary cohort data from each target region. External validation used data from seven cohorts [Clinical Practice Research Datalink, SWEDEHEART, the international REduction of Atherothrombosis for Continued Health (REACH) Registry, Estonian Biobank, Spanish Biomarkers in Acute Coronary Syndrome and Biomarkers in Acute Myocardial Infarction (BACS/BAMI), the Norwegian COgnitive Impairment After STroke, and Bialystok PLUS/Polaspire] and included 369 044 individuals with established ASCVD of whom 62 807 experienced an ASCVD event. C-statistics ranged from 0.605 [95% confidence interval (CI) 0.547-0.664] in BACS/BAMI to 0.772 (95% CI 0.659-0.886) in REACH Europe high-risk region. The clinical utility of the model was demonstrated across a range of clinically relevant treatment thresholds for intensified treatment options. CONCLUSION: The SMART2 risk score provides an updated, validated tool for the prediction of recurrent ASCVD events in patients with established ASCVD across European and non-European populations. The use of this tool could allow for a more personalized approach to secondary prevention based upon quantitative rather than qualitative estimates of residual risk.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Hageman, McKay, Ueda, et al. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. Eur Heart J. 2022. PMID: 35165703. doi:10.1093/eurheartj/ehac056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。